5a-Reductases: Mapping pathways of Metabolic Disease

5-alpha reductase inhibitors reduce the symptoms of benign prostate hyperplasia but also the breakdown of glucocorticoid in liver. Excess glucocorticoids are well recognised to induce metabolic and cardiovascular diseases. This project aims to investigate the link between 5-alpha reductase and progression of cardiometabolic diseases through (1) the investigation of electronic health datasets, including THINS, SCI-DC, and NHIRD (Taiwan), and (2) SNP and eQTL studies to construct the downstream regulatory networks of 5-alpha reductase.